Leerink Partners Starts Equillium and Protagonist Coverage
Leerink Partners began covering Equillium with an Outperform rating and lifted Protagonist Therapeutics’ price target to $190 from $150.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Dow Jones Newswires reported that Leerink Partners has assumed coverage of Equillium with an Outperform rating. The ratings action was listed in Benzinga’s analyst-ratings section.
Leerink Partners also initiated coverage of Protagonist Therapeutics with an Outperform rating. In addition, the firm raised the company’s price target to $190.00 a share from $150.00. Dow Jones Newswires and Benzinga reported the action.
why it matters
The analysts’ decisions provide fresh valuation references for EQ and PTGX. The higher target for Protagonist Therapeutics indicates a changed assessment by Leerink Partners, but it does not guarantee future share performance.
instruments
sources
- Equillium Coverage Assumed by Leerink Partners at Outperform — Dow Jones Newswires, 12 October 2026 at 12:39 UTC
- Protagonist Therapeutics Coverage Assumed by Leerink Partners at Outperform — Dow Jones Newswires, 12 October 2026 at 13:03 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗